Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.84
-0.27 (-2.43%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Monte Rosa Therapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Buy Initiates $17 → $19 | Buy | Initiates | $17 → $19 | +75.28% | Oct 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +130.63% | Oct 5, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 2, 2026 |
| Wedbush | Wedbush | Buy Maintains $27 | Buy | Maintains | $27 | +149.08% | Oct 2, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $28 | Buy | Maintains | $28 | +158.30% | Oct 2, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $37 | Buy | Reiterates | $37 | +241.33% | Oct 2, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $27 | Buy | Maintains | $27 | +149.08% | Aug 11, 2026 |
| Jefferies | Jefferies | Buy Maintains $25 | Buy | Maintains | $25 | +130.63% | Jul 31, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.